[{"orgOrder":0,"company":"PhorMed","sponsor":"WeFunder","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"12-O-Tetradecanoylphorbol-13-acetate","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"PhorMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhorMed \/ WeFunder","highestDevelopmentStatusID":"6","companyTruncated":"PhorMed \/ WeFunder"},{"orgOrder":0,"company":"PhorMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"12-O-Tetradecanoylphorbol-13-acetate","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"PhorMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhorMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PhorMed \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for 12-O-Tetradecanoylphorbol-13-acetate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Funding will support Phormed's RP-323 development, which may modulate malignant cell differentiation via multiple pathways, evaluated in patients with acute respiratory distress syndrome.

                          Product Name : RP-323

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 22, 2024

                          Lead Product(s) : 12-O-Tetradecanoylphorbol-13-acetate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : WeFunder

                          Deal Size : $5.0 million

                          Deal Type : Funding

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : These studies have generated positive results showing RP-323 (12-O-tetradecanoylphorbol-13-acetate) significantly reduces the influx of inflammatory cells into the lungs thereby limiting damage to the lungs.

                          Product Name : RP-323

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 08, 2022

                          Lead Product(s) : 12-O-Tetradecanoylphorbol-13-acetate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank